Bilirubin and uric acid serum levels in patients with relapsing-remitting multiple sclerosis after the first phase of cladribine treatment

Authors

  • Katarzyna Łobejko Department of Neurology, Medical University of Lublin Author
  • Krystyna Mitosek-Szewczyk Department of Neurology, Medical University of Lublin Author https://orcid.org/0000-0002-0474-693X
  • Jacek Kurzepa Department of Biochemistry and Molecular Biology, Medical University of Lublin Author https://orcid.org/0000-0002-7524-8831
  • Jerzy Berbecki Department of Neurology, Medical University of Lublin Author
  • Zbigniew Stelmasiak Department of Neurology, Medical University of Lublin Author

DOI:

https://doi.org/10.12923/

Abstract

Bilirubin (Bil) and uric acid (UA), endogenous antioxidant compounds, can be involved in the pathogenesis of multiple sclerosis (MS). Our goal was to find the influence of 2-chlorodeoxyadenosine (cladribine), applied for MS treatment, on Bil and UA serum levels. Twenty patients aged 24-45 years (12 female patients) with relapsing-remitting (RR) MS were enrolled. The observation period covered the first phase (three months) of cladribine infusion. The drug was administrated monthly at a dosage of 5 mg/ day s.c. for four consecutive days. Neurological examination (Expanded Disability Status Scale, EDSS) and venous blood samples were obtained before each treatment. The cladribine influence on UA and Bil serum levels was statistically insignificant. The average EDSS score of the study group (5.60±0.97) did not change during the study period. The inverse correlation of mean Bil serum level with EDSS score was observed (r = -0.53, p = 0.01, linear regression). An analogous relationship between UA and EDSS score was not noticed (r = 0.05, p > 0.05, linear regression). The inverse relationship between mean Bil serum level versus EDSS score confirmed the relationship of antioxidative species with the neurological status of MS patients.

References

1. Amorini A. M., Petzold A., Tavazzi B. et al.: Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin. Bioch., 42, 1001, 2009.

2. Bandukwala F., Huang M., Zaltzman J. S. et al.: Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am. J. Cardiol., 103, 867, 2009.

3. Carrieri P.B., Maiorino A., Provitera V. et al.: Cytokines in the pathogenesis of multiple sclerosis. Acta Neurol. Napoli, 14, 333, 1992.

4. Dujmovic I., Pekmezovic T., Obrenovic R. et al.: Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis. Clin. Chem. Lab. Med., 47, 848, 2009.

5. Ersoy M. A., Selek S., Celik H. et al.: Role of oxidative and antioxidative parameters in etiopathogenesis and prognosis of panic disorder. Int. J. Neurosci., 118, 1025, 2008.

6. Gasse P., Riteau N., Charron S. et al.: Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Resp. Crit. Care Med., 179, 903, 2009.

7. Gonsette R.E.: Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci., 274, 48, 2008.

8. Guerrero A.L., Martín-Polo J., Laherrán E. et al.: Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur. J. Neurol., 15, 394, 2008.

9. Karadi R. V., Palkar M. B., Gaviraj E.N. et al.: Antiurolithiatic Property of Moringa oleifera Root Bark. Pharm Biol., 46, 861, 2008.

10. Langtry H. D., Lamb H. M.: Cladribine: a review of its use in multiple sclerosis. BioDrugs, 9, 419, 1998.

11. Liu Y., Li P., Lu J., Xiong W. et al.: Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J. Immunol., 181, 1887, 2008.

12. Minelli A., Bellezza I., Tucci A. et. al.: Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells. Prostate, 69, 538, 2009.

13. Peng F,. Zhang B., Zhong X. et al.: Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult. Scler., 14, 188, 2008.

14. Schonwald S.: Antineoplastic drugs. In C.D. Richard (Ed.), Medical Toxicology (p. 502)., Lippincott Williams & Wilkins, Philadelphia 2004.

15. Spurgeon S., Yu M., Phillips J. D. et al.: Cladribine: not just another purine analogue? Expert Opin Inv Drug, 18, 1169, 2009.

16. Stelmasiak Z., Solski J., Nowicki J. et al.: Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult. Scler., 15, 767, 2009.

17. Tremlett H., Seemüller S., Zhao Y., et al.: Liver test abnormalities in multiple sclerosis: findings from placebo-treated patients. Neurology, 67, 1291, 2006.

Annales Sectio DDD, XXIII, 1

Downloads

Published

2025-04-04

Issue

Vol. 23 No. 1 (2010): Annales UMCS, Pharmacia, Sectio DDD, Volume XXIII

Section

Artykuły

License

Copyright (c) 2010 Authors

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.